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Background: Cats are the major source of indoor inhalant allergens after house dust
mites. The global incidence of cat allergies is rising sharply, posing a major public
health problem. Ten cat allergens have been identified. The major allergen
responsible for symptoms is Fel d 1, a secretoglobin and not a lipocalin, making the
cat a special case among mammals.
Main body: Given its clinical predominance, it is essential to have a good knowledge of
this allergenic fraction, including its basic structure, to understand the new exciting
diagnostic and therapeutic applications currently in development. The recent arrival
of the component-resolved diagnosis, which uses molecular allergens, represents a
unique opportunity to improve our understanding of the disease. Recombinant Fel d 1
is now available for in vitro diagnosis by the anti-Fel d 1 specific IgE assay. The first
part of the review will seek to describe the recent advances related to Fel d 1 in terms
of positive diagnosis and assessment of disease severity. In daily practice, anti-Fel d 1
IgE tend to replace those directed against the overall extract but is this attitude
justified? We will look at the most recent arguments to try to answer this question. In
parallel, a second revolution is taking place thanks to molecular engineering, which
has allowed the development of various forms of recombinant Fel d 1 and which seeks
to modify the immunomodulatory properties of the molecule and thus the clinical
history of the disease via various modalities of anti-Fel d 1-specific immunotherapy.
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